Latest News
Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
Company Overview
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. Connect with us on X, LinkedIn and Facebook.
Latest Financial Results
Q1 2025
Quarter Ended Mar 31, 2025
Sign up for
email alerts
Be the first to receive breaking news
Sign Up TodayIR Contacts
Company
Corbus Pharmaceuticals Holdings, Inc.
500 River Ridge Drive
Norwood, MA 02062
T: 617.963.0100
info@corbuspharma.com
Investor Relations
Corbus Pharmaceuticals
Sean Moran
Chief Financial Officer
ir@corbuspharma.com
LifeSci Advisors, LLC
Bruce Mackle
Managing Director
T: 617.415.7745
bmackle@lifesciadvisors.com
Transfer Agent
Continental Stock Transfer & Trust Company
17 Battery Place
New York, NY 10004
T: 800.509.5586
cstmail@continentalstock.com
https://www.continentalstock.com